Skip to content

US · MRKR · BIOTECHNOLOGY

Marker Therapeutics, Inc. (MRKR) intrinsic value and stock valuation

$1.09as of 2026-11-21 · Mkt cap 12.09M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Marker Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values MRKR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MRKR’s statements →

Marker Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77021 markertherapeutics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-12.16M
20112025
Free cash flow
-$-12.01M
20112025
Total equity
$16.8M-9.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$6.59M$3.31M$3.51M$1.24M
Operating income-$-12.89M-$-11.12M-$-14.58M-$-19.79M-$-39.48M
Net income-$-12.16M-$-10.73M-$-8.24M-$-29.93M-$-41.88M
EPSd-$-794.25K-$-1.19M-$-935.3K-$-3.58M-$-5.47M
Operating cash flow-$-12.01M-$-10.91M-$-16.44M-$-26.97M-$-27.28M
Capital expenditure$0.00$0.00$0.00$0.00-$-3.13M
Free cash flow-$-12.01M-$-10.91M-$-16.44M-$-26.97M-$-30.41M
Total assets$19.1M$22M$17.1M$34.4M$68.1M
Total debt$0.00$0.00$0.00$7.62M$11.9M
Net debt-$-16.07M-$-19.19M-$-15.11M-$-4.17M-$-30.48M
Total equity$16.8M$18.6M$14.1M$19.6M$44M
Cash and short-term investments$16.1M$19.2M$15.1M$11.8M$42.4M
Income statement
20252024202320222021
Revenue$0.00$6.59M$3.31M$3.51M$1.24M
Cost of revenue$0.00$13.5M$10.4M$12M$3.16M
Gross profit$0.00-$-6.88M-$-7.11M-$-8.45M-$-1.92M
Research and development expenses$11.8M$13.5M$10.4M$12M$27.8M
Selling, general and administrative expenses$4.18M$4.24M$7.48M$11.3M$9.76M
Other expenses-$-3.09M-$-13.47M-$-10.42M-$-11.97M$0.00
Operating expenses$12.9M$4.24M$7.48M$11.3M$37.6M
Cost and expenses$12.9M$17.7M$17.9M$23.3M$40.7M
Interest income$590K$440K$540K$250K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$2.79M$2.79M$3.16M
Ebitda-$-12.44M-$-10.68M-$-11.25M-$-16.99M-$-38.72M
Operating income-$-12.89M-$-11.12M-$-14.58M-$-19.79M-$-39.48M
Total other income/expenses, net$710K$440K$540K$20K-$-2.4M
Income before tax-$-12.18M-$-10.68M-$-14.04M-$-19.78M-$-41.88M
Income tax expense-$-20K$50K$0.00$0.00$0.00
Net income-$-12.16M-$-10.73M-$-8.24M-$-29.93M-$-41.88M
Weighted average shares outstanding$15.3M$8.98M$8.81M$8.35M$7.65M
Weighted average diluted shares outstanding$15.3M$8.98M$8.81M$8.35M$7.65M
Balance sheet
20252024202320222021
Cash and short-term investments$16.1M$19.2M$15.1M$11.8M$42.4M
Net receivables$1.37M$2.35M$1.03M$2.4M$0.00
Inventory$0.00$0.00-$-990K$0.00$0.00
Total current assets$19.1M$22M$17.1M$16.6M$46M
Property, plant and equipment, net$0.00$0.00$0.00$17.8M$22.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$17.8M$22.2M
Total assets$19.1M$22M$17.1M$34.4M$68.1M
Accounts payable$790K$1.07M$960K$1.1M$5.14M
Short-term debt$0.00$0.00$0.00$580K$620K
Deferred revenue$970K$0.00$0.00$2.5M$1.15M
Total current liabilities$2.27M$3.46M$3.07M$7.78M$12.9M
Long-term debt$0.00$0.00$0.00$7.04M$11.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$7.04M$11.3M
Capital lease obligations$0.00$0.00$0.00$7.62M$11.9M
Total liabilities$2.27M$3.46M$3.07M$14.8M$24.2M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-459.18M-$-447.02M-$-436.29M-$-428.05M-$-398.12M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$16.8M$18.6M$14.1M$19.6M$44M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$7.62M$11.9M
Net debt-$-16.07M-$-19.19M-$-15.11M-$-4.17M-$-30.48M
Cash flow statement
20252024202320222021
Net income-$-12.16M-$-10.73M-$-14.05M-$-19.78M-$-41.88M
Depreciation and amortization$0.00$0.00$0.00$3.68M$3.16M
Stock-based compensation$540K$250K$860K$3.3M$0.00
Change in working capital-$-390K-$-420K$2.85M-$-4.76M$5.47M
Accounts receivable$980K-$-1.32M$1.37M-$-2.4M$1M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-450K$10K$610K$0.00$4.14M
Net cash provided by operating activities-$-12.01M-$-10.91M-$-16.44M-$-26.97M-$-27.28M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00-$-3.13M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$18.7M-$-4.95M-$-3.13M
Common stock issued$9.86M$14.9M$1.01M$200K$52.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.86M$15M$1.11M$200K$52.6M
Net change in cash-$-2.15M$4.08M$3.33M-$-31.72M$22.1M
Cash at end of period$17M$19.2M$15.1M$11.8M$43.5M
Operating cash flow-$-12.01M-$-10.91M-$-16.44M-$-26.97M-$-27.28M
Capital expenditure$0.00$0.00$0.00$0.00-$-3.13M
Free cash flow-$-12.01M-$-10.91M-$-16.44M-$-26.97M-$-30.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Marker Therapeutics, Inc.

        Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

        CEO
        Juan F. Vera
        Employees
        5
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of Marker Therapeutics, Inc. (MRKR)?

        InvestorsCraft does not currently publish an intrinsic value for MRKR. How the IC value is calculated.

        Is MRKR undervalued?

        InvestorsCraft does not publish an undervaluation signal for MRKR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.